Efficacy and Tolerability of an Intra-Nasal Testosterone Product

Completed · Phase 2

Conditions studied: Hypogonadism

In brief

This clinical trial is being performed to compare the pharmacokinetic profile of testosterone after repeated intra-nasal administration of products of different strengths in subjects with hypogonadism.

Key facts

Study ID

NCT00975650

Run by

Acerus Pharmaceuticals Corporation

People needed

57

Starts

2009-08-01

Expected to finish

2010-05-01

Last updated by the study team

2018-08-13

Who can join

Age: 18 and older, up to 80. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Men with primary or secondary hypogonadism and a serum morning (0900 h ± 30 minutes) testosterone levels >100 ng/dl and ≤ 300 ng/dL.
• Normal Otolaryngological nasal endoscopy examination.
• Normal prostate examination (no palpable prostatic mass), and serum PSA ≤ 4.0 ng/mL.

You may not qualify if…

• Current treatment with other androgens (i.e. DHEA), anabolic steroids or other sex hormones
• Treatment with Estrogens, GnRH antagonists, or Growth Hormone within previous 12 months
• History of nasal surgery, specifically turbinoplasty, septoplasty, rhinoplasty, or sinus surgery.
• History of nasal disorders (e.g. polyposis, recurrent epistaxis ( > 1 nose bleed per month, abuse of nasal decongestants) or sleep apnea.

Where it is running

• Quality of Life Medical & Research centre — Tucson, Arizona, United States
• Providence Clinical Research — Burbank, California, United States
• Cetero Research — Miami Gardens, Florida, United States
• Clinical Research Institute — Wichita, Kansas, United States
• Regional Urology, LLC — Shreveport, Louisiana, United States
• dgd Research Inc. — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.